CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,435,051 | +141423.8% | 25,562 | +2.5% | 0.02% | -15.0% |
| Q4 2022 | $1,014 | -99.9% | 24,949 | +4.4% | 0.02% | -41.2% |
| Q3 2022 | $1,561,000 | +30.5% | 23,893 | +21.4% | 0.03% | +9.7% |
| Q2 2022 | $1,196,000 | -23.7% | 19,682 | -21.2% | 0.03% | -16.2% |
| Q1 2022 | $1,568,000 | -17.2% | 24,983 | -0.0% | 0.04% | +15.6% |
| Q4 2021 | $1,894,000 | -20.5% | 24,987 | +17.4% | 0.03% | -17.9% |
| Q3 2021 | $2,383,000 | -1.7% | 21,286 | +34.4% | 0.04% | -43.5% |
| Q4 2020 | $2,425,000 | +315.2% | 15,841 | +126.9% | 0.07% | +176.0% |
| Q3 2020 | $584,000 | +57.0% | 6,983 | +37.8% | 0.02% | +38.9% |
| Q2 2020 | $372,000 | -22.0% | 5,067 | -55.0% | 0.02% | -58.1% |
| Q1 2020 | $477,000 | -53.2% | 11,249 | -32.8% | 0.04% | -6.5% |
| Q4 2019 | $1,019,000 | +159.3% | 16,733 | +94.4% | 0.05% | +253.8% |
| Q1 2018 | $393,000 | – | 8,608 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |